Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
Prospective isolation of murine and human bone marrow mesenchymal stem cells based on surface markers.
Comparison of Antioxidant Status and Vitamin D Levels between Multiple Sclerosis Patients and Healthy Matched Subjects.
Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis.
Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.
Access to Multiple Sclerosis Specialty Care.
Is a hypothetical melanoma-like neuromelanin the underlying factor essential for the aetiopathogenesis and clinical manifestations of multiple sclerosis?
Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.
Pediatric inflammatory diseases. Part I: multiple sclerosis.
Mortality following a brain tumour diagnosis in patients with multiple sclerosis.
Alterations in Immune Cells and Mediators in the Brain: It's Not Always Neuroinflammation!
Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS.
Obstructive Sleep Apnea is an Under-Recognized and Consequential Morbidity in Multiple Sclerosis.
Assessment of cortical damage in early multiple sclerosis with quantitative T2 relaxometry.
A previously misdiagnosed cohort of aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with disease duration of >10 years in multi-ethnic Penang, Malaysia: Clinical features and disease course.
Age-dependent increase of blood-brain barrier permeability and neuron-binding autoantibodies in S100B knockout mice.
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.
Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice.
GWAS and transcriptional analysis prioritize ITPR1 and CNTN4 for a serum uric acid 3p26 QTL in Mexican Americans.
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Repeatability of quantitative sodium magnetic resonance imaging for estimating pseudo-intracellular sodium concentration and pseudo-extracellular volume fraction in brain at 3 T.
Work Participation and Executive Abilities in Patients with Relapsing-Remitting Multiple Sclerosis.
Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
Keratan sulfate exacerbates experimental autoimmune encephalomyelitis.
In vivo characterization of microglial engulfment of dying neurons in the zebrafish spinal cord.
Pages
« first
‹ previous
…
683
684
685
686
687
688
689
690
691
…
next ›
last »